$ALGS News

Lake Street Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $45

Cantor Fitzgerald Initiates Coverage On Aligos Therapeutics with Overweight Rating, Announces Price Target of $20

Aligos Therapeutics (NASDAQ:ALGS) Surges After Hours on Q1 Earnings Beat

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results

Aligos Therapeutics Q1 EPS $(2.21) Beats $(2.28) Estimate, Sales $2.830M Beat $500.000K Estimate

Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aligos and Xiamen Amoytop sign deal for HBV therapy

Aligos Therapeutics Says China Pact Puts HBV Drug In Focus Amid Trial Updates

Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

Aligos Therapeutics shares are trading higher after the company announced that it has entered into an exclusive license agreement to develop and commercialize pevifoscorvir sodium with Xiamen Amoytop Biotech

Aligos Therapeutics shares are trading higher after the company announced that it has entered into an exclusive license agreement to develop and commercialize pevifoscorvir sodium with Xiamen Amoytop Biotech

Aligos Therapeutics Enters Exclusive License Agreement With Xiamen Amoytop Biotech To Develop And Commercialize Pevifoscorvir Sodium In Greater China, With Upfront Payment Of $25M And Eligibility To Receive Up To $420M In Milestones

Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation

Aligos Therapeutics Announces First Interim Analysis Results From Phase 2 B-SUPREME Study; FDA Grants Fast Track Designation

WestPark Capital Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $48

Jefferies Assumes Aligos Therapeutics at Buy, Lowers Price Target of $48

HC Wainwright & Co. Reiterates Buy on Aligos Therapeutics, Maintains $50 Price Target

Aligos Therapeutics Inc (NASDAQ:ALGS) Reports Q4 Revenue Miss, Highlights 2026 Clinical Catalysts

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results